NCT00751166 is a Phase 4 clinical trial of Desloratadine in Urticaria, sponsored by Organon and Co.

Who is sponsoring NCT00751166?

NCT00751166 is sponsored by Organon and Co.

What drugs are being tested in NCT00751166?

Interventions in NCT00751166: Desloratadine, Cetirizine, placebo.

Is NCT00751166 still recruiting?

NCT00751166 is currently terminated. Last updated 15 August 2024.

Last reviewed 2024-08-15 · How we verify

NCT00751166

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736)

Terminated Phase 4 Last updated 15 August 2024

What this trial tests

Phase 4 trial testing Desloratadine in Urticaria in 149 participants. Terminated before completion.

Timeline

1 March 2004

Primary endpoint
1 May 2005

1 May 2005

Quick facts

Lead sponsor	Organon and Co
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	149
Start date	1 March 2004
Primary completion	1 May 2005
Estimated completion	1 May 2005

Drugs / interventions tested

Desloratadine (desloratadine) — full drug profile →
Cetirizine (cetirizine) — full drug profile →
placebo

Conditions studied

Urticaria — all drugs for Urticaria →

Sponsor

Organon and Co — full company profile →

Who can join

Adults 12 to 70, any sex, with Urticaria. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This was a randomized, double-blind, parallel-group, multicenter study that used both an active control (cetirizine) and a placebo control to evaluate desloratadine 5 mg once daily during a 28-day treatment period. The active treatments and placebo were allocated in a 2:2:1 ratio.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

H1-antihistamines for chronic spontaneous urticaria.
Sharma M, Bennett C, Cohen SN, Carter B. · · 2014 · cited 22× · PMID 25397904 · DOI 10.1002/14651858.cd006137.pub2

Verify or expand the search:

Other trials of Desloratadine

Trials testing the same drug.

NCT07486583 — Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients. · Phase 3 · not yet recruiting
NCT06916884 — Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Deslor · Phase 3 · recruiting
NCT05214911 — Fixed Dose Combination of Desloratadine / Prednisolone in the Treatment of Moderate Severe Allergic Rhinitis in Children · Phase 3 · completed
NCT06268470 — Antiplatelet Therapy in Chronic Urticaria · Phase 2 · unknown
NCT01916967 — An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201) · Phase 3 · completed

Other Organon and Co trials

Trials by the same sponsor.

NCT05761444 — Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients · Phase 4 · completed
NCT05789576 — A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Regi · Phase 4 · completed
NCT05680740 — A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis · Phase 4 · completed
NCT05560646 — A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 · Phase 2 · completed
NCT05264506 — Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive · Phase 3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00751166 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Organon and Co
Last refreshed: 15 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00751166.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing